- Home
- ACRS vs MRAM Comparison
ACRS vs MRAM Comparison
Compare ACRS & MRAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- MRAM
- Stock Information
- Founded
- ACRS 2012
- MRAM 2008
- Country
- ACRS United States
- MRAM United States
- Employees
- ACRS N/A
- MRAM N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- MRAM Semiconductors
- Sector
- ACRS Health Care
- MRAM Technology
- Exchange
- ACRS Nasdaq
- MRAM Nasdaq
- Market Cap
- ACRS 132.0M
- MRAM 140.4M
- IPO Year
- ACRS 2015
- MRAM 2016
- Fundamental
- Price
- ACRS $2.72
- MRAM $6.23
- Analyst Decision
- ACRS Strong Buy
- MRAM Strong Buy
- Analyst Count
- ACRS 5
- MRAM 2
- Target Price
- ACRS $8.75
- MRAM $9.00
- AVG Volume (30 Days)
- ACRS 1.1M
- MRAM 136.7K
- Earning Date
- ACRS 11-06-2024
- MRAM 10-30-2024
- Dividend Yield
- ACRS N/A
- MRAM N/A
- EPS Growth
- ACRS N/A
- MRAM N/A
- EPS
- ACRS N/A
- MRAM 0.07
- Revenue
- ACRS $27,079,000.00
- MRAM $53,865,000.00
- Revenue This Year
- ACRS N/A
- MRAM N/A
- Revenue Next Year
- ACRS N/A
- MRAM $7.15
- P/E Ratio
- ACRS N/A
- MRAM $87.36
- Revenue Growth
- ACRS 26.35
- MRAM N/A
- 52 Week Low
- ACRS $0.86
- MRAM $4.89
- 52 Week High
- ACRS $5.17
- MRAM $9.43
- Technical
- Relative Strength Index (RSI)
- ACRS 41.17
- MRAM 49.14
- Support Level
- ACRS $2.91
- MRAM $6.19
- Resistance Level
- ACRS $3.29
- MRAM $6.68
- Average True Range (ATR)
- ACRS 0.29
- MRAM 0.26
- MACD
- ACRS -0.18
- MRAM -0.01
- Stochastic Oscillator
- ACRS 0.75
- MRAM 29.22
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About MRAM Everspin Technologies Inc.
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA); and Asia-Pacific (APAC).